Tabrecta and Swelling - a phase IV clinical study of FDA data

Summary:

Swelling is reported as a side effect among people who take Tabrecta (capmatinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Eliquis, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Swelling when taking Tabrecta. It is created by eHealthMe based on reports of 2,093 people who have side effects when taking Tabrecta from the FDA, and is updated regularly.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. eHealthMe is studying from 2,095 Tabrecta users. Check the latest studies of Tabrecta.

What is Swelling?

Swelling is found to be associated with 2,297 drugs and 2,894 conditions by eHealthMe. Check the latest studies of Swelling.

On Jul, 12, 2026

2,093 people reported to have side effects when taking Tabrecta.
Among them, 68 people (3.25%) have Swelling.

Among these 68 people:

How long have people been on Tabrecta when they have Swelling? *

What is the gender of people who have Swelling when taking Tabrecta? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Swelling when taking Tabrecta? *

What are other drugs people take besides Tabrecta? *

What are other side effects people have besides Swelling? *

Fatigue (feeling of tiredness): 25 people, 36.76%
Peripheral Swelling: 24 people, 35.29%
Dyspnea (difficult or laboured breathing): 13 people, 19.12%
Nausea (feeling of having an urge to vomit): 13 people, 19.12%
Neoplasm Malignant (cancer tumour): 8 people, 11.76%
Weakness: 8 people, 11.76%
Dizziness: 7 people, 10.29%
Gait Disturbance: 7 people, 10.29%
Memory Loss: 7 people, 10.29%
Oedema (fluid collection in tissue): 7 people, 10.29%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 13 people, 19.12%
Lung Cancer - Non-Small Cell (lung cancer): 7 people, 10.29%
Neoplasm Malignant (cancer tumour): 3 people, 4.41%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 3 people, 4.41%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 2.94%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 1.47%
Prostate Cancer: 1 person, 1.47%
Neuralgia (pain in one or more nerves): 1 person, 1.47%

* Approximation only. Some reports may have incomplete information.

Do you take Tabrecta and have Swelling?

- Check whether Swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tabrecta:

Tabrecta (2,095 reports)

Swelling treatments and more:

Swelling (115,742 reports)

Browse all side effects of Tabrecta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Swelling:

Swelling (2,297 drugs)

Browse all the conditions that are associated with Swelling:

Swelling (2,894 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on capmatinib hydrochloride (the active ingredients of Tabrecta) and Tabrecta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.